# ImmunityBio Inc.

Type: Company (IBRX)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/immunitybio-inc
Canonical HTML page: https://gethealthbrief.com/entity/immunitybio-inc

## Timeline

- **2026-Q3**: Expected Regional Launch — Anticipated availability of ANKTIVA in Macau oncology centers.
- **2026-03-25**: Macau SAR Approval — Macau Health Bureau grants regulatory clearance for ANKTIVA.
- **2024-05-15**: U.S. Commercial Launch — ImmunityBio begins commercial distribution of ANKTIVA in the U.S.
- **2024-04-22**: U.S. FDA Approval — ANKTIVA receives first-ever approval for NMIBC in the United States.

## Recent coverage (1 stories)

### ImmunityBio Secures Macau Approval for ANKTIVA, Eyeing Chinese Oncology Market
2026-03-25 16:46:17 · Sentiment: Positive · Impact: 7/10 · Sources: 2

ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.
Full story: https://gethealthbrief.com/story/immunitybio-anktiva-macau-approval-china-expansion

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.